Ewa Lech-Maranda

Institute of Hematology and Transfusion Medicine

Poland

Research Interests

Explore related searches

Professors in Poland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (11)

Year:

2025

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (11)

IRENA MISIEWICZ-KRZEMINSKA

Instytut Hematologii i Transfuzjologii

POLAND

View details

Anna Czyz

Medical University of Silesia

POLAND

View details

Agnieszka Wierzbowska

Medical University of Lodz

POLAND

View details

Tamas Masszi

Professor

Semmelweis University

HUNGARY

View details

PIER LUIGI ZINZANI

University of Bologna

ITALY

View details

Przemysław Juszczyński

Professor

Institute of Hematology and Transfusion Medicine

POLAND

View details

Tycel Phillips

University of Michigan Medical School

UNITED STATES

View details

Małgorzata Sobczyk-Kruszelnicka

Maria Sklodowska-Curie National Research Institute of Oncology

POLAND

View details

Joanna Barankiewicz

Instytut Hematologii i Transfuzjologii

POLAND

View details

Bozena Katarzyna Budziszewska

Institute of Hematology and Transfusion Medicine

POLAND

View details

Katarzyna Borg

Assistant of Professor / Head of Laboratory

Institute of Hematology and Transfusion Medicine

POLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ewa Lech-Maranda

Research Interests

Explore related searches

Contact this professor

Articles (11)

Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study

Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

Antimicrobial prophylaxis in adults and children undergoing hematopoietic cell transplantation: 2021 Polish recommendations.

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 tria

Cladribine combined with low-dose cytarabine as frontline treatment for unfit elderly acute myeloid leukemia patients: results from a prospective multicenter study of Polish Adult Leukemia Group (PALG).

Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

The CRBN, CUL4A and DDB1 Expression Predicts the Response to Immunomodulatory Drugs and Survival of Multiple Myeloma Patients

Trudności w leczeniu chorego na ostrą białaczkę szpikową z mutacją FLT3-ITD i wysokim stosunkiem allelicznym — oporność na standardową chemioterapię indukującą w połączeniu z midostauryną

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study

Collaborators (11)

IRENA MISIEWICZ-KRZEMINSKA

Anna Czyz

Agnieszka Wierzbowska

Tamas Masszi

PIER LUIGI ZINZANI

Przemysław Juszczyński

Tycel Phillips

Małgorzata Sobczyk-Kruszelnicka

Joanna Barankiewicz

Bozena Katarzyna Budziszewska

Katarzyna Borg

Make your next move.